DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Information source: Novo Nordisk A/S
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Diabetes; Diabetes Mellitus, Type 2

Intervention: repaglinide (Drug); glyburide (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Novo Nordisk A/S

Official(s) and/or principal investigator(s):
Paula Hale, Study Director, Affiliation: Novo Nordisk A/S

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

Clinical Details

Official title: Repaglinide Versus Glyburide: Comparitive Effect on Postprandial Lipemia: An Open-labeled, Randomized, Parallel Group Study in Patients With Type 2 Diabetes

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Triglyceride levels post standardised fat tolerance test

Secondary outcome:

Incidence of hypoglycemic episodes

Change in HbA1c (glycosylated haemoglobin A1c)

Change in FPG (fasting plasma glucose)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Newly diagnosed patients with type 2 diabetes currently treated with diet and

exercise alone (HbA1c below 10%)

- Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8. 5%)

- Males or non-pregnant, non-lactating females

- Subjects should have normal renal function

Exclusion Criteria:

- Type 1 or other specific causes of diabetes

- Marked symptomatic diabetes

- Uncontrolled treated/untreated hypertension

- Known or suspected allergy to the trial products or related products

Locations and Contacts

Novo Nordisk Clinical Trial Call Center, Houston, Texas 77030, United States
Additional Information

Clinical Trials at Novo Nordisk

Starting date: November 2001
Last updated: August 30, 2012

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017